tbuckley/cabot-search huggingface dataset:
Abstract 169: Elucidating the role of GRK5 in Physiological Hypertrophy
Authors: Christopher J Traynham, Alessandro Cannavo, Jonathan Hullmann, Jessica L Gold, Walter J Koch
Journal: Circulation Research (2014)

Cardiac function is dynamically regulated by various G protein-coupled receptors (GPCRs). GPCR kinases (GRKs) are important in cardiac GPCR regulation through phosphorylation and desensitization of these receptors. GRK2 and GRK5 are the predominant GRKs in the heart, and the most widely characterized as they are both up-regulated in the failing heart. Prior studies from our Lab have determined that GRK5 plays a crucial role in pathological cardiac hypertrophy. Another type of hypertrophy termed, “physiological hypertrophy” occurs with exercise training and is defined as an enlargement in cardiac myocyte size leading to favorable cardiac adaptations. At present, it is unclear if GRK5 is a regulator of physiological hypertrophy in addition to its role in maladaptive hypertrophy. We hypothesize that GRK5 will not regulate physiological hypertrophy such that mice with cardiac-specific overexpression of GRK5 (TgGRK5) will yield a similar post-exercise cardiac physiological hypertrophic response as that of control wild-type (WT) mice. To test this hypothesis, TgGRK5 and WT mice were exposed to a 21 day high-intensity swimming exercise protocol. For each line, sham mice, which did not swim served as appropriate controls. At the conclusion of this protocol, mice were sacrificed and heart weight (HW), body weight (BW), and tibia length (TL) measured. TgGRK5 and WT mice both exhibited a characteristic 10-15% increase in HW/BW and HW/TL ratios, which are standard measures of cardiac hypertrophy. In addition, hearts were sectioned and H&amp;E stained to evaluate myocyte size. Both TgGRK5 and WT mice exhibited a significant increase in myocyte size. Cardiac function was evaluated via echocardiography both prior to and after exercise training, and no changes were observed between TgGRK5 and WT mice after training. These data were re-affirmed in H9C2 cells and neonatal rat ventricular myocytes overexpressing either GFP or GRK5, which exhibited similar increases in cell size and AKT phosphorylation after IGF-1 treatment, a physiological hypertrophy stimulus. Taken together, these data suggest that physiological hypertrophy is similar in both control and TgGRK5 mice, confirming that GRK5 is solely a regulator of pathological cardiac hypertrophy.
Virus-Induced Pancreatic Cancer in Guinea Fowl: A Morphologic Study
Authors: Todor T. Kirev, Ilia A. Toshkov, Zahary M. Mladenov
Journal: JNCI Journal of the National Cancer Institute (1986)

The morphologic lesions in the pancreas of 350 guinea fowls infected with avian osteopetrosis virus strain Pts-56 were studied. Focal unspecific changes in the acinar tissue, including reduction of zymogen content, diminution of cytoplasm, and dilatation of acinar lumens accompanied with substitution of the affected acini by tubular structures lined with centroacinar-like cells, developed 2 months from post infection (p.i.) in about 30% of the birds. Adenomatous growths of ductules with mucin-producing or mucin-nonproducing epithelium were observed independently or parallelly to these changes after 3 months p.i. Pancreatic carcinomas arose as early as 4 months p.i. The number and size of the neoplastic foci increased with time, and after the 6th month neoplastic foci were established in almost all infected guinea fowls. Neoplastic proliferations of type A and D endocrine cells were identified in the carcinoma foci of separate cases. Other associated neoplasms were bone tumors and papillomatous growths of the duodenal mucosa.
P1331 : Phase 3B studies to assess long-term clinical outcomes in HCV GT1-infected patients treated with ombitasvir/ paritaprevir/ritonavir and dasabuvir with or without ribavirin
Authors: E.O. Dumas, J. Enejosa, G. Ball, Y.B. Hu, M. Co, R. Kumar Pothacamury, Y. Liu, N. Shulman, T. Podsadecki
Journal: Journal of Hepatology (2015)
Operative Treatment of Aortic Stenosis in the Elderly Patient
Authors: J. Gordon Scannell, W. Gerald Austen
Journal: New England Journal of Medicine (1964)

IT is now well established that calcific aortic stenosis may be a surgical problem, although questions of optimum technics and surgical indications remain.1 2 3 4 5 6 7 It has been our belief that, except in rare cases, only patients with significant symptoms of angina, syncope or congestive heart failure should be subjected to surgery. At the same time we have not considered age a contraindication to surgery and have believed that the elderly patient with significant symptoms should not be denied surgical treatment. Thus, during the past six years, we have performed open aortic valvuloplasty on 3 patients who were seventy or more years . . .
Altered Multidrug Resistance Phenotype Caused by Anthracycline Analogues and Cytosine Arabinoside in Myeloid Leukemia
Authors: Xiu F. Hu, Alison Slater, Phillip Kantharidis, Danny Rischin, Surender Juneja, Ralph Rossi, Grace Lee, John D. Parkin, John R. Zalcberg
Journal: Blood (1999)
Progress in Exercise Stress Imaging of the Pulmonary Circulation and RV
Authors: Robert Naeije
Journal: JACC. Cardiovascular imaging (2016)

Exercise stress measurements have been used since the early years of cardiac catheterization [(1)][1]. A mean pulmonary artery pressure (mPAP) >30 mm Hg during exercise was an entry criterion for the U.S. National Institutes of Health’s registry of primary pulmonary hypertension, now called
Phase I Dose-Escalation Study to Determine the Maximum Tolerated Dose (Mtd) of Nintedanib (Bibf 1120) in Combination with Carboplatin/Pegylated Liposomal Doxorubicin (Pld) in Patients (Pts) with Recurrent Ovarian Cancer (Roc)
Authors: J.M. Del Campo, B. Pardo Búrdalo, V. Rodriguez Freixinos, L. Gaba Garcia, M. Gil Martín, A. Oaknin, A. Ballester, M.O. Sailer, M. Merger, N. Morsli, L. Vidal
Journal: Annals of Oncology (2014)
ARRESTED TUBERCULOSIS.SUBSEQUENT HISTORIES OF SEVENTY-NINE ARRESTED CASES TREATED AT THE SHARON SANITARIUM FROM 1891 TO 1902.
Authors: VINCENT Y. BOWDITCH
Journal: JAMA (1903)

Four years ago I had the pleasure of giving the subsequent histories of thirty-four "arrested" cases of pulmonary disease treated at the Sharon Sanitarium from 1891 up to 1899.<sup>1</sup>I will not apologize for bringing up the subject again, for all will agree that it is the after-histories of such cases which prove the efficacy or otherwise of methods which are now so prominently before the public. Let me again cite the fact that these results have been obtained in a climate thought to be most unfavorable for consumptives, not far from the sea-coast and at the insignificant altitude of between 200 and 300 feet only above sea-level. In these latter particulars the Sharon Sanitarium was for several years unique. During recent years, Dr. Millet's sanatorium at East Bridgewater has been built with similar conditions, although it is intended for patients who are of a more well-to-do class than
The borderline adult: therapeutic alliance and transference
Authors: J F Masterson
Journal: American Journal of Psychiatry (1978)

The author suggests that successful therapy with borderline patients requires the initiation, strengthening, and maturation of the therapeutic alliance as well as the working-through of the patient's difficulty with separation-individuation from the past. He defines a borderline transference as the activation and alternative projection on the therapist of the patient's primitive, split, positive, and negative object relations part-units. In the process of therapy confrontation and, later, interpretation bring these part-units to the patient's awareness, where they can be worked through and the separation-individuation process failure repaired. The therapist who deals with borderline patients must have both personal maturity and professional skill.
A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study
Authors: Herve Ghesquieres, Susan L Slager, Fabrice Jardin, Amelie S Veron, Anne Novak, Matthew J Maurer, Thierry Fest, Thomas M Habermann, Marie C Bene, Corinne Haioun, Thierry Lamy, Stephen M Ansell, Herve Tilly, Thomas E Witzig, Andrew L. Feldman, Ahmet Dogan, Julie M Cunningham, Curtis L Olswold, Yan W Asmann, Thierry Jo Molina, Brian K Link, Noel Milpied, David G Cox, Gilles Andre Salles, James R Cerhan
Journal: Blood (2013)
A phase III randomized, double-blind, placebo controlled trial of North American (NA) ginseng (Panax quinquefolium) extract (CVT-E002) in patients with chronic lymphocytic leukemia: Effect on respiratory infection and antibiotic use.
Authors: K. P. High, L. D. Case, R. D. Siegel, J. Metzner-Sidurski, J. C. Krauss, B. Chinnasami, G. H. Sanders, S. Rousey, G. J. Lesser, E. G. Shaw
Journal: Journal of Clinical Oncology (2010)

6578 Background: Chronic lymphocytic leukemia (CLL) is the most common adult leukemia and patients are at high risk for respiratory infection. Methods: We investigated the safety and efficacy of an extract of NA ginseng, CVT-E002 (200 mg po bid) to reduce acute respiratory illness (ARI) in CLL patients during Jan-Mar, 2009 in a randomized, placebo-controlled trial. 293 subjects with untreated CLL were enrolled through the Community Clinical Oncology Programs affiliated with Wake Forest University Cancer Center’s Research Base as well as NCI Cancer Trials Study Unit sites. ARI symptoms were recorded in daily diaries and rated (0 = absent; 1 = mild, 2 = moderate, 3 = severe). Results: Median subject age was 66 (range 43-87), 57% were male, and 77% of subjects had received influenza vaccine. Medication compliance was > 97% for both CVT-E002 and placebo. CVT-E002 was well tolerated with no difference in adverse events between groups. 50% of CVT-E002 recipients experienced ≥ 1 ARI day vs. 55% of placebo recipients (absolute diff -5%, 95% C.I. -16%,7%). 27% of CVT-E002 recipients experienced ≥ 1 severe ARI day (ARI + fever and/or limited activity) vs. 30% of placebo recipients (absolute diff -3%, 95% C.I. -14%,7%). When only mod-severe symptoms were considered, ARI occurred in 31% of CVT-E002 recipients vs. 39% in the placebo group (absolute diff -8%, 95% C.I. -19%,3%) There was no difference in mean ARI days (8.2 ± 16.8 in CVT-E002 recipients vs. 6.8 ± 13.3 in placebo) or antibiotic use. Examination of secondary endpoints (e.g. serologically confirmed viral infections, immunologic parameters) is ongoing. Conclusions: CVT-E002 did not reduce the mean number of ARI days, although there was a trend toward a lower incidence of ARI and mod-severe ARI. CVT-E002 was well tolerated. Supported by Afexa Life Sciences and NIH/NCI/DCP grant 3 U10 CA 81851. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Afexa Life Sciences
Lean body shape is linked to lowest mortality, research shows
Authors: Jacqui Wise
Journal: BMJ (2016)

People who maintain a stable lean body shape throughout their lifetime have the lowest mortality, while those with a heavy body shape from childhood to middle age have the highest, a large study published in The BMJ has found.1

Researchers tracked the evolution of body shape and the associated mortality among two large cohorts. A total of 80 266 women and 36 622 men in the Nurses’ Health Study and the Health Professionals Follow-up Study were asked to recall their body shape at ages 5, 10, 20, 30, and 40. They also provided their body mass index (BMI) at age …
No differences of response to telaprevir based therapy in cirrhotic and non cirrhotic patients with RVR: a real life data from South Italy. Hepatology 2014; 60 (S1): 695A-696A. Abstract. 1018
Authors: M Persico, M Masarone, S Camera, Rosato, R Granata, Gg Di Costanzo, C Coppola, N Coppola, As Megna, Ivan Gentile, A De Luna, A Federico, Df Precone, E Claar, Filomena Morisco
Journal: Hepatology (2014)
Mixed Diagnoses and Mixed Messages
Authors: Jeffrey A. Linder, Mark W. Friedberg
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
The Effect of Concomitant Treatment With SSRIs and Statins: A Population-Based Study
Authors: Ole Köhler, Christiane Gasse, Liselotte Petersen, Katja G Ingstrup, Andrew A Nierenberg, Ole Mors, Søren D Østergaard
Journal: American Journal of Psychiatry (2016)

Both preclinical studies and clinical trials have indicated that the combination of a selective serotonin reuptake inhibitor (SSRI) and a statin may have superior antidepressant effects compared with SSRI treatment alone. The authors sought to assess whether this beneficial effect can be generalized to a more heterogeneous population of SSRI users.In a nationwide cohort study that included all incident SSRI users in Denmark between 1997 and 2012, the authors compared people who had periods of concomitant use of SSRIs and statins with people who had periods of SSRI treatment alone. Outcomes included the rates of psychiatric hospital contacts (any cause), psychiatric hospital contacts due to depression, suicidal behavior, and all-cause mortality. Using Cox regression and competing risk analysis, the authors calculated crude and adjusted hazard ratios for these outcomes.The authors identified 872,216 incident SSRI users, of whom 113,108 (13.0%) used a statin concomitantly. Compared with SSRI treatment alone, the combined use of an SSRI and a statin was associated with a significantly lower risk for both psychiatric hospital contacts (adjusted hazard ratio=0.75 (95% CI=0.69, 0.82) and psychiatric hospital contacts due to depression (adjusted hazard ratio=0.64, 95% CI=0.55, 0.75). Compared with SSRI treatment alone, the concomitant use of SSRIs and statins was not associated with significant increases in all-cause mortality (adjusted hazard ratio=1.04, 95% CI=0.96, 1.12) or suicidal behavior (adjusted hazard ratio=0.85, 95% CI=0.61, 1.18).In a large naturalistic cohort, concomitant treatment with SSRIs and statins resulted in robust advantages compared with SSRIs alone.
ATPS-65AN ONCOLYTIC MYXOMA VIRUS CONSTRUCT (M011L KNOCK-OUT) INDUCES APOPTOSIS AND IS A POTENT PRO-APOPTOTIC THERAPY IN BOTH HUMAN AND IMMUNOCOMPETENT MURINE GLIOBLASTOMA CANCER STEM CELLS MODELS
Authors: Alexandra Pisklakova, Brienne McKenzie, Franz Zemp, Rajappa Kenchappa, Grant McFadden, Peter Forsyth
Journal: Neuro-Oncology (2015)

BACKGROUND: GBM is a deadly brain cancer with an average survival of 12 months. In the past, a treatment-resistant Brain Tumor Initiating Cell (BTIC) compartment has been identified and is thought to drive tumor recurrence. One experimental strategy to target BTICs is the use of oncolytic viruses (OVs). A number of studies have found that OVs may be used to target BTICs in vivo and that some require the innate or acquired immune response for their efficacy. Myxoma Virus (MyxV-WT) is a promising oncolytic virus that is highly effective against glioma cell lines but less effective for BTICs. We hypothesized that MyxV virally encoded anti-apoptotic proteins is a limiting factor for oncolytic efficacy in BTICs. By manipulating MyxV-WT and genetic deletion of the anti-apoptotic gene M11L we will have better therapeutic efficacy and enhanced cell death in BTICs that might be synergistic with conventional Temozolomide therapy. RESULTS: We utilized a panel of patient-derived BTICs and developed syngeneic mBTIC line arising in Trp53+/-/Nf1+/- mice. We compared the efficacy of the MyxV-WT with the MyxV, in which the anti-apoptotic protein M011L has been deleted. We found that MyxV-M011L-KO induced significant amount of intrinsic apoptosis as compared to MyxV-WT, resulting in robust BTICs cell death. Silencing the Bax significantly blocked the induction of apoptosis and cell death induced by MyxV-M011L-KO. Using immunocompetent orthotopic syngeneic glioma model, we found that M011L-KO treatment statistically prolonged survival (38 days) as compared to WT or inactivated virus (30 and 27 days respectively) whereas addition of clinical relevant dose of TMZ resulted in 50% long-term survival rate (>90 days). In contrast, MYXV-M011L-KO treatment in SCID models, failed to provide significant survival advantage in both human and murine BTICs. These results suggest that intact immune response is critical factor regulating oncolytic efficacy of MYXV-M011L-KO in vivo.
GENO-32AN ANATOMIC TRANSCRIPTIONAL ATLAS OF GLIOBLASTOMA
Authors: Ralph Puchalski (co-presenter), Nameeta Shah (co-presenter), Jeremy Miller, Rachel Dalley, Steve Nomura, Jae-Guen Yoon, Michael Lankerovich, Xu Feng, Fuhui Long, Amy Bernard, Lydia Ng, Ed Lein, John Phillips, Chinh Dang, Steve Rostad, Bart Keogh, Farrokh Farrokhi, Charles Cobbs, Mike Hawrylycz, Greg Foltz
Journal: Neuro-Oncology (2015)

The molecular and cellular landscape of glioblastoma is highly complex and its relationship to histologic features routinely used for diagnosis is unclear. To investigate this relationship, we generated an anatomic transcriptional atlas of human glioblastoma, adopting a highly-systematized, large-scale, histology-driven approach to the characterization of anatomic features and cancer stem cell populations. The atlas of 42 tumors consists of several data modalities, including 270 transcriptomes, ∼11,500 semi-annotated pathology images registered to ∼23,000 in situ hybridization gene expression images, ∼400 MRI scans, tumor-derived cell lines and xenografts, and supporting longitudinal clinical information. We show that gene expression varies considerably by anatomic feature and cancer stem cell population, exhibiting molecular signatures that are more highly conserved within tumors than between tumors, and reflecting the cell types and microenvironment of each feature and population. These freely-accessible online data resources of the Ivy Glioblastoma Atlas Project (Ivy GAP), one for the fully-annotated anatomic transcriptional atlas (http://glioblastoma.alleninstitute.org/), and one for the detailed clinical and genomic data (http://ivygap.org/), constitute a unique platform for exploring the anatomic and genetic basis of glioblastoma at the cellular and molecular levels. This project was supported by grants from the Ben and Catherine Ivy Foundation to the Allen Institute (PI, RBP) and Swedish Neuroscience Institute (PIs, GDF and NS).
Chemotactic Response Toward Chemokines and Its Regulation by Transforming Growth Factor-β1 of Murine Bone Marrow Hematopoietic Progenitor Cell-Derived Different Subset of Dendritic Cells
Authors: Masafumi Ogata, Yi Zhang, Yong Wang, Meiji Itakura, Yan-yun Zhang, Akihisa Harada, Shin-ichi Hashimoto, Kouji Matsushima
Journal: Blood (1999)
Revascularization in Patients With Multivessel Coronary Artery Disease and Severe Left Ventricular Systolic Dysfunction
Authors: Sripal Bangalore, Yu Guo, Zaza Samadashvili, Saul Blecker, Edward L. Hannan
Journal: Circulation (2016)

Guidelines recommend coronary artery bypass graft surgery (CABG) over percutaneous coronary intervention (PCI) for multivessel disease and severe left ventricular systolic dysfunction. However, CABG has not been compared with PCI in such patients in randomized trials.Patients with multivessel disease and severe left ventricular systolic dysfunction (ejection fraction ≤35%) who underwent either PCI with everolimus-eluting stent or CABG were selected from the New York State registries. The primary outcome was long-term all-cause death. Secondary outcomes were individual outcomes of myocardial infarction, stroke, and repeat revascularization. Among the 4616 patients who fulfilled our inclusion criteria (1351 everolimus-eluting stent and 3265 CABG), propensity score matching identified 2126 patients with similar propensity scores. In the short term, PCI was associated with a lower risk of stroke (hazard ratio [HR], 0.05; 95% confidence interval [CI], 0.01-0.39; P=0.004) in comparison with CABG. At long-term follow-up (median, 2.9 years), PCI was associated with a similar risk of death (HR, 1.01; 95% CI, 0.81-1.28; P=0.91), a higher risk of myocardial infarction (HR, 2.16; 95% CI, 1.42-3.28; P=0.0003), a lower risk of stroke (HR, 0.57; 95% CI, 0.33-0.97; P=0.04), and a higher risk of repeat revascularization (HR, 2.54; 95% CI, 1.88-3.44; P<0.0001). The test for interaction was significant (P=0.002) for completeness of revascularization, such that, in patients in whom complete revascularization was achieved with PCI, there was no difference in myocardial infarction between PCI and CABG.Among patients with multivessel disease and severe left ventricular systolic dysfunction, PCI with everolimus-eluting stent had comparable long-term survival in comparison with CABG. PCI was associated with higher risk of myocardial infarction (in those with incomplete revascularization) and repeat revascularization, and CABG was associated with higher risk of stroke.
Slic-Seg: A minimally interactive segmentation of the placenta from sparse and motion-corrupted fetal MRI in multiple views
Authors: Guotai Wang, Maria A. Zuluaga, Rosalind Pratt, Michael Aertsen, Tom Doel, Maria Klusmann, Anna L. David, Jan Deprest, Tom Vercauteren, Sébastien Ourselin
Journal: Medical Image Analysis (2016)

Segmentation of the placenta from fetal MRI is challenging due to sparse acquisition, inter-slice motion, and the widely varying position and shape of the placenta between pregnant women. We propose a minimally interactive framework that combines multiple volumes acquired in different views to obtain accurate segmentation of the placenta. In the first phase, a minimally interactive slice-by-slice propagation method called Slic-Seg is used to obtain an initial segmentation from a single motion-corrupted sparse volume image. It combines high-level features, online Random Forests and Conditional Random Fields, and only needs user interactions in a single slice. In the second phase, to take advantage of the complementary resolution in multiple volumes acquired in different views, we further propose a probability-based 4D Graph Cuts method to refine the initial segmentations using inter-slice and inter-image consistency. We used our minimally interactive framework to examine the placentas of 16 mid-gestation patients from MRI acquired in axial and sagittal views respectively. The results show the proposed method has 1) a good performance even in cases where sparse scribbles provided by the user lead to poor results with the competitive propagation approaches; 2) a good interactivity with low intra- and inter-operator variability; 3) higher accuracy than state-of-the-art interactive segmentation methods; and 4) an improved accuracy due to the co-segmentation based refinement, which outperforms single volume or intensity-based Graph Cuts.